Characterization of primary human skeletal muscle cells from multiple commercial sources

In Vitro Cellular and Developmental Biology - Animal

Volumn 49, Issue 9, 2013, Pages 695-705

  Owens, Jane ^a   Moreira, Karen ^a   Bain, Gerard ^a,b  

^a PFIZER INC   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

Atrophy; Hypertrophy; Myoblast; Myotube; Skeletal muscle cell differentiation

Indexed keywords

ADENOVIRIDAE; ANIMALIA;

ARTICLE; CELL DIFFERENTIATION; CYTOLOGY; DRUG INDUSTRY; GENETICS; HUMAN; PRIMARY CELL CULTURE; SKELETAL MUSCLE;

CELL DIFFERENTIATION; DRUG INDUSTRY; HUMANS; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; PRIMARY CELL CULTURE;

EID: 84886423170     PISSN: 10712690     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11626-013-9655-8     Document Type: Article

References (28)

1. Baudy A.; Saxena H.; Gordish H.; Hoffman E.; Nagaraju K. A robust in vitro screening assay to identify NF-kappaB inhibitors for inflammatory muscle diseases. Int. Immunopharmacol. 9: 1209-1214; 2009.
2. Berger M.; Doherty T. Sarcopenia: prevalence, mechanisms and functional consequences. Interdiscip. Top. Gerontol. 37: 94-114; 2010.
3. Bigot A.; Jacquemin V.; Debacq-Chainiaux F.; Butler-Browne G.; Toussaint O.; Furling D.; Mouly V. Replicative aging down-regulates the myogenic regulatory factors in human myoblasts. Biol. Cell 100: 189-199; 2008. (Pubitemid 351372677)
4. Black B.; Olson E. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu. Rev. Cell Dev. Biol. 14: 167-196; 1998. (Pubitemid 29001453)
5. Burattini S.; Ferri P.; Battistelli M.; Curci P.; Luchetti F.; Falcieri E. C2C12 murine myoblasts as a model of skeletal muscle development: morpho-functional characterization. Eur. J. Histochem. 48: 223-234; 2004.
6. Cho Y.; Kim C.; Cheon H. Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase 1 inhibitors. Anal. Biochem. 392: 110-116; 2009.
7. Cornelison D.; Wold B. Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev. Biol. 191: 270-283; 1997. (Pubitemid 28282912)
8. Cui Z.; Chen X.; Lu B.; Park S.; Xu T.; Xie Z.; Xue P.; Hou J.; Hang H.; Yates J.; Yang F. Preliminary quantitative profile of differential protein expression between rat L6 myoblasts and myotubes by stable isotope labeling with amino acids in cell culture. Proteomics 9: 1274-1292; 2009.
9. Dogra C.; Changotra H.; Mohan S.; Kumar A. Tumor Necrosis Factor-like Weak Inducer of Apoptosis Inhibits Skeletal Myogenesis through Sustained Activation of Nuclear Factor-κB and Degradation of MyoD Protein. J. Biol. Chem. 281: 10327-10336; 2006. (Pubitemid 43864571)
10. Dogra C.; Changotra H.; Wedhas N.; Qin X.; Wergedal J.; Kumar A. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 21: 1857-1869; 2007a. (Pubitemid 46855631)
11. Dogra C.; Hall S.; Wedhas N.; Linkhart T.; Kumar A. Fibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes. Evidence for TWEAK-independent functions of Fn14 during myogenesis. J. Biol. Chem. 282: 15000-15010; 2007b. (Pubitemid 47093382)
12. Duan C.; Ren H.; Gao S. Insulin-like growth factors (IGFs), IGF receptors and IGF-binding proteins: role in skeletal muscle growth and differentiation. Gen. Comp. Endocrinol. 167: 344-351; 2010.
13. Girgenrath M.; Weng S.; Kostek C.; Browning B.; Wang M.; Brown S.; Winkles J.; Michaelson J.; Allaire N.; Schneider P.; Scott M.; Hsu Y.; Yagita H.; Flavell R.; Boone Miller J.; Burkly L.; Zheng T. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J. 25: 5826-5839; 2006. (Pubitemid 44967766)
14. Jankowski R (2011) A comparison of commercially-available human skeletal muscle cells and media for research applications. Nature Methods/Application Notes. http://www.nature.com/app-notes/nmeth/2011/111406/full/an7998.html.
15. Lecomte V.; Meugnier E.; Euthine V.; Durand C.; Freyssenet D.; Nemoz G.; Rome S.; Vidal H.; Lefai E. A new role for sterol regulatory element binding protein 1 transcription factors in the regulation of muscle mass and muscle cell differentiation. Mol. Cell. Biol. 30: 1182-1198; 2010.
16. Lee S. J. Regulation of muscle mass by myostatin. Annu. Rev. Cell Dev. Biol. 20: 61-86; 2004. (Pubitemid 39488633)
17. Lee S. J.; Reed L.; Davies M.; Girgenrath S.; Goad M.; Tomkinson K.; Wright J.; Barker C.; Ehrmantraut G.; Holmstrom J.; Trowell B.; Gertz B.; Jiang M.-S.; Sebald S.; Matzuk M.; Li E.; Liang L.; Quattlebaum E.; Stotish R.; Wolfman N. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. U. S. A. 102: 18117-18122; 2005. (Pubitemid 41798511)
18. McFarlane C.; Plummer E.; Thomas M.; Hennebry A.; Murray A.; Ling N.; Smith H.; Sharma M.; Kambadur R. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. 209: 501-514; 2006. (Pubitemid 44484641)
19. Megeney L.; Rudnicki M. Determination versus differentiation and the MyoD family of transcription factors. Biochem. Cell Biol. 73: 723-732; 1995.
20. Ozernyuk N.; Balan O. Muscle satellite cells and regulation of recovery potential of muscle. Biol. Bull. 34: 542-550; 2007. (Pubitemid 350209103)
21. Pistilli E.; Bogdanovich S.; Goncalves M.; Ahima R.; Ahima R.; Lachey J.; Seehra J.; Khurana T. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am. J. Pathol. 178: 1287-1297; 2011.
22. Rebbapragada A.; Benchabane H.; Wrana J.; Celeste A.; Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 23: 7230-7242; 2003. (Pubitemid 37211004)
23. Semsarian C.; Sutrave P.; Richmond D.; Graham R. Insulin-like growth factor (IGF-1) induces myotube hypertrophy associated with an increase in anaerobic glycolysis in a clonal skeletal-muscle cell model. Biochem. J. 339(Pt 2): 443-451; 1999. (Pubitemid 29209977)
24. Stitt T.; Drujan D.; Clarke B.; Panaro F.; Timofeyva Y.; Kline W.; Gonzalez M.; Yancopoulos G.; Glass D. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 14: 395-403; 2004. (Pubitemid 38591410)
25. Sultan K.; Henkel B.; Terlou M.; Haagsman H. Quantification of hormone-induced atrophy of large myotubes from C2C12 and L6 cells: atrophy-inducible and atrophy-resistant C2C12 myotubes. Am. J. Physiol. Cell Physiol. 290: C650-C659; 2006.
26. Thies R.; Chen T.; Davies M.; Tomkinson K.; Pearson A.; Quazi S.; Wolfman N. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors 18: 251-259; 2001. (Pubitemid 32776305)
27. Zammit P.; Partridge T.; Yablonka-Reuveni Z. The skeletal muscle satellite cell: the stem cell that came in from the cold. J. Histochem. Cytochem. 54: 1177-1191; 2006. (Pubitemid 44623339)
28. Zhao W.; Qin W.; Pan J.; Wu Y.; Bauman W.; Cardozo C. Dependence of dexamethasone-induced Akt/FOXO1 signaling, upregulation of MAFbx, and protein catabolism upon the glucocorticoid receptor. Biochem. Biophys. Res. Commun. 378: 668-672; 2009.